Sodium-Glucose Transporter 2 (SGLT2) inhibitors increase the urinary excretion of glucose, allowing a reduction of glycaemia, and are recommended in patients with type 2 diabetes.[6,7] Currently, some studies have described potential protective effects against progressive renal events and hospitalization rates due to HF.[8] Some authors have proposed that SGLT2 inhibitors promotes the fasting transcriptional paradigm, and increases ketone bodies, which changes the myocardial metabolism and raises antioxidant and anti-inflammatory effects.[9]. The gene discussed is SLC5A2; the disease is hydrops fetalis.